… The development of common variable immunodeficiency (CVID) or hypogammaglobulinemia
in systemic lupus erythematosus (SLE) is rare. The purpose of this article is to provide a …

OBJECTIVE: Transverse myelitis (TM) is a rare complication of systemic lupus erythematosus
(SLE). Although usually a late manifestation of SLE, it can occur at presentation. We …

Current evidence indicates that regulatory T cells (Tregs) actively suppress autoreactive
lymphocytes that escape central tolerance. 1 2 Tregs are characterised by a high intensity CD25 …

Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin
10 in systemic lupus erythematosus - Mellor‐Pita - 2009 - Cytometry Part B: Clinical …

Objectives Metabolic syndrome (MetS) is highly prevalent in patients with systemic lupus
erythematosus (SLE) and it has been associated with increased cardiovascular risk. We …

The purpose of this study was to examine the expression of human leukocyte antigen-G (HLA-G)
in patients with systemic lupus erythematosus (SLE) and its relation with interleukin-10 (…

… Overall, the mortality rate in our population was 6.41%, with a 2.79% mortality rate per
admission, which is in agreement with the literature [5,6,19,26,30]. However, it is noteworthy that …

… the burden of comorbidities as described in our cohort, who is exposed to SARS-CoV-2. …
However, we believe that the lack of this data is compensated by the size of the study population…

Background: Not all the patients with sarcoidosis need pharmacological therapy, and the
decision to start therapy is based mainly on clinical conditions. The aim of this study was to …

… Unlike previous reports showing that venous thrombosis is the most frequent
manifestation of APS (2, 15), most thrombotic events leading to admission in this study were …